Literature DB >> 19561631

Cetuximab, chemotherapy and KRAS status in mCRC.

Sharlene Gill, Richard M Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19561631     DOI： 10.1038/nrclinonc.2009.83

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

Authors:  Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

2.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

3.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

4.  Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

Authors:  D Arnold; T Höhler; C Dittrich; F Lordick; T Seufferlein; J Riemann; E Wöll; T Herrmann; A Zubel; H-J Schmoll
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

Review 5.  KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

Authors:  Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

6.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Authors:  J Randolph Hecht; Edith Mitchell; Tarek Chidiac; Carroll Scroggin; Christopher Hagenstad; David Spigel; John Marshall; Allen Cohn; David McCollum; Philip Stella; Robert Deeter; Seta Shahin; Rafael G Amado
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

7.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

9.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245
  9 in total
  6 in total

Review 1.  Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.

Authors:  Steve C Lee; Raghvendra M Srivastava; Andrés López-Albaitero; Soldano Ferrone; Robert L Ferris
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 2.  Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity.

Authors:  Sumita Trivedi; Hyun-Bae Jie; Robert L Ferris
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

3.  Pharmacogenetics and personal genomes.

Authors:  Michael J Wagner
Journal:  Per Med       Date:  2009-11-01       Impact factor: 2.512

Review 4.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 5.  The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

Authors:  Steven C Smith; Alexander S Baras; Jae K Lee; Dan Theodorescu
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

6.  CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.

Authors:  Yuankai Shi; Jin Li; Jianming Xu; Yan Sun; Liwei Wang; Ying Cheng; Wei Liu; Guoping Sun; Yigui Chen; Li Bai; Yiping Zhang; Xiaohui He; Yi Luo; Zhehai Wang; Yunpeng Liu; Qiang Yao; Yuhong Li; Shukui Qin; Xiaohua Hu; Feng Bi; Rongsheng Zheng; Xuenong Ouyang
Journal:  Cancer Commun (Lond)       Date:  2019-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.